Table 1.
Patient and disease characteristics of trial and non-trial participants by donor type
| Characteristic | Trial two-unit UCB | Non-trial two-unit UCB | Trial Haplo-BM | Non-trial Haplo-BM | Non-trial Haplo-PE |
|---|---|---|---|---|---|
| Number | 183 | 195 | 154 | 358 | 403 |
| Sex | |||||
| Male | 92 (50) | 105 (54) | 91 (59) | 194 (54) | 209 (52) |
| Female | 91 (50) | 90 (46) | 63 (41) | 164 (46) | 194 (48) |
| Age- median (min-max) | 58 (20-71) | 58 (19-70) | 60 (20-71) | 56 (18-70) | 58 (18-70 |
| Race | |||||
| White | 140 (77) | 141 (72) | 108 (70) | 253 (71) | 284 (70) |
| Black or African American | 27 (15) | 25 (13) | 28 (18) | 52 (15) | 89 (22) |
| Other | 13 (7) | 23 (12) | 15 (10) | 30 (8) | 15 (4) |
| Not Reported | 3 (2) | 6 (3) | 3 (2) | 23 (6) | 15 (4) |
| Performance score | |||||
| 90-100 | 125 (68) | 124 (64) | 97 (63) | 258 (72) | 208 (52) |
| 70-80 | 58 (32) | 71 (36) | 57 (37) | 100 (28) | 195 (48) |
| Cytomegalovirus serostatus | |||||
| Negative | 78 (43) | 68 (35) | 63 (41) | 144 (40) | 135 (33) |
| Positive | 104 (57) | 127(65) | 91 (59) | 212(59) | 263 (65) |
| Not Reported | 1 (1) | 0 (0) | 0 (0) | 2 (1) | 5 (1) |
| Co-morbidity score | |||||
| ≤2 | 110 (60) | 87 (45) | 91 (59) | 210(59) | 208 (52) |
| >3 | 73 (40) | 108 (55) | 63 (41) | 145 (41) | 190 (47) |
| Not Reported | 0(0) | 0(0) | 0(0) | 3(1) | 5(1) |
| Disease | |||||
| Acute lymphoblastic leukemia | 31 (17) | 21 (11) | 26 (17) | 66 (18) | 53 (13) |
| Acute myeloid leukemia | 96 (52) | 130 (67) | 86 (56) | 157 (44) | 220 (55) |
| Biphenotypic leukemia | 1 (1) | 3 (2) | 5 (3) | 3 (1) | 3 (1) |
| Hodgkin lymphoma | 10 (5) | 8 (4) | 8 (5) | 37 (10) | 29 (7) |
| Large cell lymphoma | 21 (11) | 12 (6) | 16 (10) | 40 (11) | 34 (8) |
| Follicular lymphoma | 8 (4) | 5 (3) | 3 (2) | 11 (3) | 17 (4) |
| T-Cell lymphoma | 3 (2) | 11 (6) | 1 (1) | 20 (6) | 29 (7) |
| Mantle cell lymphoma | 6 (3) | 3 (2) | 3 (2) | 11 (3) | 10 (2) |
| Other lymphoma | 7 (4) | 2 (1) | 6 (4) | 13 (4) | 8 (2) |
| Disease Status | |||||
| Leukemia | |||||
| 1st complete remission | 95 (52) | 114 (58) | 98 (64) | 179 (50) | 211 (52) |
| 2nd complete remission | 33 (18) | 39 (20) | 18 (12) | 43 (12) | 56 (14) |
| 3rd complete remission | — | 1 (1) | 1 (1) | 4 (1) | 9 (2) |
| Lymphoma | |||||
| Complete remission | 24 (13) | 25 (13) | 13 (8) | 73 (20) | 63 (16) |
| Partial remission | 23 (13) | 11 (6) | 21 (14) | 48 (13) | 47 (12) |
| Follicular Lymphoma | 8 (4) | 5 (3) | 3 (2) | 11 (3) | 17 (4) |
| Disease risk index | |||||
| Low | 24 (13) | 18 (9) | 12 (8) | 43 (12) | 54 (13) |
| Intermediate | 123 (67) | 161 (83) | 107 (69) | 248 (69) | 271 (67) |
| High/ Very High | 36 (20) | 16 (8) | 35 (24) | 67 (19) | 78 (19) |
| Follow-up, median (range), months | 48 (12-80) | 58 (12-79) | 47 (7-76) | 48 (8-97) | 36 (6-74) |